Organogenesis Holdings Inc.
corporate_fare Company Profile
Organogenesis Holdings Inc. (NASDAQ:ORGO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ORGO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ORGO spans 8-K, 424B5, 10-Q, 10-K.
Recent high-impact activity:
- Organogenesis Taps $75M At-the-Market Equity Program to Shore Up Liquidity
- Organogenesis Launches $75M ATM Equity Program After Q2 Revenue Plunge and Guidance Cut
- Organogenesis Q2 Revenue Plunges 58%, Loss Widens to $96M; Guidance Slashed
- FDA Accepts ReNu BLA for Knee OA; Organogenesis Sets April 2027 PDUFA Date
- Organogenesis Reports Steep Q1 Revenue Decline and Widened Loss Amid Restructuring, Achieves Positive Operating Cash Flow
Financial Snapshot
Short Interest & Short Volume
18.82 days to coverFINRA reported short interest of 14,119,761 shares in ORGO as of the September 15, 2026 settlement, a 0.9% decrease from the prior period — about 18.8 days to cover at its recent average daily volume. On October 2, 2026, 74.2% of ORGO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ORGO, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
$75M ATM Program Established · Dilution Overhang at Depressed Prices
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →